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Hyperphosphatemia in chronic kidney disease (CKD) patients
is a potentially life altering condition that can lead to cardiovas-
cular calciﬁcation, metabolic bone disease (renal osteodystro-
phy) and the development of secondary hyperparathyroidism
(SHPT). To effectively manage hyperphosphatemia in CKD
patients it is important to not only consider pharmacological
and non-pharmacological treatment options but also to under-
stand the underlying physiologic pathways involved in phos-
phorus homoeostasis. This review will therefore provide both
a background into phosphorus homoeostasis and the manage-
ment of hyperphosphatemia in CKD patients. In addition, it
will cover some of the most important reasons for failure to
control hyperphosphatemia with emphasis on the effect of the
gastric pH on phosphate binders efﬁciency.
Phosphorus is the second most abundant element in the
human body after calcium (Bellasi et al., 2006). The majority
(85%) of phosphorus is found in bone and teeth as hydroxyap-
atite (Uribarri, 2007; Bellasi et al., 2006), 14% is located intra-
cellularly as organic phosphate compounds; with the
remaining 1% of the total body phosphate located extracellu-
larly, mainly as inorganic phosphate (Bellasi et al., 2006;
Uribarri, 2007). Of the 1% located in the vascular space,
20% is protein bound (Uribarri, 2007).
Inorganic phosphate is a component of many organic com-
pounds and cell structures such as phospholipid cell mem-
branes, nucleic acids, and phosphoproteins (Berndt et al.,
2005). It plays signiﬁcant roles in many biological processes
such as cell signalling, synthesis of nucleic acid, energy metab-
olism, membrane functions, bone mineralisation and carbohy-
drate metabolism (Berndt and Kumar, 2007; Xie et al., 2000).
In addition, it is essential for the normal generation of red
blood cells, white blood cells and platelet function (Berndt
et al., 2005). Phosphate is sourced for adenosine triphosphate
synthesis, a critical energy source for physiological processes
such as muscle contractility, neurological activities, electrolyte
transportation, and other biological reactions (Nishi et al.,
2011). Given the importance of phosphate for varied andmultiple biological processes, it is not surprising that phosphate
homoeostasis is a complex and highly regulated processes.
2. Phosphate homoeostasis in humans
In healthy adults, most laboratories quote a normal phosphate
reference concentration range of 0.80–1.45 mmol/L (Berndt
and Kumar, 2007). Overall intake and excretion is determined
by the net balance of ingested and absorbed phosphate from
food, and phosphate excretion through the bowels and the uri-
nary tract (Hahn et al., 1937). In addition, the plasma phos-
phate concentration is also inﬂuenced by the rate of bone
formation and resorption, since phosphate moves in and out
of the bone (Berndt et al., 2005; Weidmann, 1956; Hahn
et al., 1937).
2.1. Intestinal absorption
The average ingested phosphate content from dietary intake is
in the order of 20 mg/kg/day (see Fig. 1) and it is typically
found in foods that are rich in protein such as dairy products,
meats, eggs, and cereals as well as food additives that contain
phosphate (Schaefer, 1994; Berndt et al., 2005; Bellasi et al.,
2006). The bioavailability of phosphate from a vegetarian diet
is relatively low compared to meat dietary protein (Moe et al.,
2011). Phosphorus from plant sources is mostly in the form of
phytate, which is not hydrolysable by humans due the lack of
phytase enzyme and hence, is not absorbable (Moe et al.,
2011). Vegetarians would therefore be expected to ingest less
phosphate compared to non-vegetarians.
Of the total amount of daily ingested phosphate, 16 mg/kg/
day is usually absorbed by the intestine and approximately
3 mg/kg/day is secreted back into the intestine through pancre-
atic and intestinal secretions (Berndt et al., 2005). The remain-
ing 7 mg/kg/day of unabsorbed phosphate is excreted via the
faecal route (Berndt et al., 2005).
The major sites for phosphate absorption are in the jeju-
num and ileum (Bellasi et al., 2006; Xie et al., 2000; Katai
et al., 1999). The absorption process is carried out both by
Figure 1 Phosphate homoeostasis in humans used with permission (Berndt and Kumar, 2007).
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system inﬂuenced by sodium-phosphate co-transporters (NaPi
co-transporters), that account for about 60% of ‘‘normal’’ die-
tary phosphate absorption (Bellasi et al., 2006; Xie et al., 2000;
Katai et al., 1999; Danisi et al., 1990; Danisi et al., 1980). This
percentage can increase up to 80% under the inﬂuence of the
active form of vitamin D (1a, 25(OH)2D3) and be reduced to
40% if a patient is taking phosphate binders (Bellasi et al.,
2006; Cupisti et al., 2003).
Sodium-phosphate co-transporters (NaPi co-transporters)
are carrier systems present in the brush border membranes
of intestine and renal proximal tubular cells and are responsi-
ble for phosphate absorption from the intestine and reabsorp-
tion from proximal tubules of the kidney (Bellasi et al., 2006;
Berndt et al., 2005; Moe et al., 2011). By modulating
these co-transporters, many factors (discussed later) can alter
intestinal phosphate absorption and inﬂuence phosphate
homoeostasis.
2.2. Renal elimination
The kidney plays a major role in phosphate homoeostasis
(Kay, 1926). The kidneys excrete the total net amount of
absorbed phosphate (13 mg/kg/day) (Berndt et al., 2005).
Under normal physiological condition, in healthy individuals
phosphate is freely ﬁltered through the glomerulus. The major-
ity (85–90%) of ﬁltered phosphate undergoes tubular reab-
sorption primarily in proximal tubules (Miyamoto et al.,
1995; Miyamoto et al., 1997; Baumann et al., 1975)
(Uribarri, 2007).
3. Factors affecting phosphate homoeostasis
There is signiﬁcant interplay between factors that inﬂuence
calcium and phosphate homoeostasis. The inﬂuences are
further complicated in patients with impaired renal function.Factors that regulate phosphate homoeostasis principally alter
phosphate absorption from the intestine, reabsorption from
kidney and mobilisation from and/or uptake by the bone. To
understand potential inﬂuences it is critical to review this inter-
play especially with regard to Parathyroid Hormone (PTH)
and ﬁbroblast growth factor-23 (FGF23).
3.1. Parathyroid hormone (PTH)
PTH plays a vital role in the regulation of both calcium and
phosphate homoeostasis.
Parathyroid glands contain calcium-sensing receptors that
sense the extracellular ionised calcium concentration and regu-
late PTH secretion (Garrett et al., 1995; Riccardi et al., 1995).
If ionised calcium is reduced (with increased serum phosphate
concentration (Patwardhan and Nhavi, 1939; McGowan,
1933)), PTH will be released and exert its phosphaturic effect
directly on the kidney (Sutcliffe et al., 1973). In addition,
PTH stimulates osteoclast activity in the bone to release cal-
cium and phosphate into the extracellular pool, and also stim-
ulate the activation of vitamin D to 1a,25(OH)2D3 via the 1a-
hydroxylase enzyme (Uy et al., 1995; Garabedian et al., 1972).
PTH also reduces the number of NaPi co-transporters in
the proximal tubules, leading to reduced phosphate reabsorp-
tion and therefore greater excretion of phosphate by the kid-
ney (Goadby and Stacey, 1934; O’Donovan et al., 1993).
This results in decreased serum phosphate, a reduction in
calcium excretion and an increase of serum calcium
concentration.
3.2. Vitamin D
Activated vitamin D (1a, 25(OH)2D3) acts on the intestine to
increase the number of NaPi co-transporters thereby increas-
ing the absorption of both phosphate and calcium (Katai
et al., 1999; Danisi et al., 1980; Danisi et al., 1990). In contrast
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uptake by the bones by stimulating osteoblast and inhibiting
osteoclast activities (Baldock et al., 2006; Dickson and
Kodicek, 1979). In addition, 1a, 25(OH)2D3 directly inhibits
PTH hormone action (Friedlaender et al., 1983) and stimulates
renal NaPi co-transporters to inhibit phosphate excretion
(Kurnik and Hruska, 1985). As serum calcium and phosphate
concentrations increase, the activity of a hydroxylase in renal
tubules is reduced thus reducing the activation of vitamin D
(Spanos et al., 1981).
3.3. Phosphatonins
Phosphatonins are a group of factors, originally identiﬁed in
patients with tumour-induced osteomalacia. They are associ-
ated with inducing hypophosphatemia, lowering concentra-
tions of vitamin D and increasing excretion of urinary
phosphate (Cai et al., 1994). Several phosphatonins have been
identiﬁed with ﬁbroblast growth factor-23 (FGF-23), ﬁbro-
blast growth factor-7, secreted frizzled-related protein and
matrix extracellular phosphoglycoprotein being the most com-
monly cited (Berndt and Kumar, 2007).
FGF-23 reduces phosphate re-uptake by inﬂuencing renal
NaPi co-transporters resulting in increased renal phosphate
excretion (Inoue et al., 2005; Shimada et al., 2004b; Shimada
et al., 2004a). In addition, FGF23 also reduces circulating
1a, 25(OH)2D3 through the inhibition of 1a-hydroxylase activ-
ity (Inoue et al., 2005; Shimada et al., 2004b; Shimada et al.,
2004a). Actions on the intestine, involve a reduction in the
number of NaPi co-transporters and consequently phosphate
absorption (Shimada et al., 2004a).
FGF-23 actions are independent of PTH and are believed
to be primarily inﬂuenced by phosphate concentrations
(Shimada et al., 2004a).
The following factors have also been reported to alter phos-
phate homoeostasis by inﬂuencing NaPi co-transporters.
(A) Factors that stimulate renal phosphate reabsorption by
NaPi co-transporters in the proximal tubules:
 Insulin-like growth factor 1 (Caverzasio et al., 1990).
 Insulin (Hammerman et al., 1984).
 Thyroid hormone (Ishiguro et al., 2010).
 Serotonin (Hafdi et al., 1996).
 Growth hormone (Hammerman et al., 1980).
 All-trans-retinoic acid (Masuda et al., 2010).(B) Factors that increase phosphate excretion by inhibiting
NaPi co-transporters in the proximal tubules:
 Dopamine (de Toledo et al., 1999).
 Calcitonin (Berndt and Knox, 1984).
 Glucocorticoids (Freiberg et al., 1982).
 Fasting (Kempson, 1985).
 Plasma volume expansion (Suki et al., 1969; Liput
et al., 1989).3.4. Dietary intake of phosphate
Evidence also suggests a regulatory inﬂuence of dietary phos-
phate on homoeostatic mechanisms (Martin et al., 2005;
Berndt et al., 2007).Low phosphate dietary intake stimulates intestinal and renal
NaPi co-transporters expression leading to increased absorption
of phosphate from the intestine and reabsorption from the prox-
imal tubules (Danisi et al., 1990; Katai et al., 1999; Stoll et al.,
1979; Jahan andButterworth, 1988). In addition, low phosphate
induces an increase in circulating 1a, 25(OH)2D3 (Danisi et al.,
1990). By contrast, high dietary phosphate intake stimulates a
rapid release of PTH to increase renal phosphate excretion
before any changes in serum calcium or phosphate concentra-
tions occur (Martin et al., 2005; Berndt et al., 2007).
3.5. Phosphate exchange from bone and intracellular
compartment
A dynamic equilibrium exists between the bone and the extra-
cellular phosphate pool. Effective homoeostasis of phosphate
requires a balance between the uptake and release of P from
bone as well as other intracellular sources (Hahn et al., 1937;
Weidmann, 1956; Dickson and Kodicek, 1979).
When considering non-skeletal cellular structures several
pathways are involved in the transport of phosphate from
the plasma to the intracellular space. Due to the electronega-
tivity of cellular membranes and concentration gradients,
active transport systems rather than passive diffusion are
required for transport (Werner and Kinne, 2001).
Changes in electronegativity gradients such as acid-base
disorders can cause transcellular shifts of phosphate between
intracellular and extracellular ﬂuids (Mostellar and Tuttle,
1964; Barsotti et al., 1986). In metabolic acidosis, phosphate
moves from inside the cell to extracellular space leading to
increase phosphate concentration in the blood (Mostellar
and Tuttle, 1964; Barsotti et al., 1986). In contrast, in case
of alkalosis, phosphate moves intracellularly and serum phos-
phate concentration is reduced (Mostellar and Tuttle, 1964;
Barsotti et al., 1986).
3.6. Diurnal variations
Diurnal ﬂuctuations in serum phosphate concentrations occur
with phosphate concentration being lowest in the early morn-
ing but increasing by 16% by midday (Havard and Reay,
1925). During an evening sleep cycle, phosphate increases by
approximately 40%, remains elevated, then drops rapidly after
awakening (Havard and Reay, 1925). There are also seasonal
variations with phosphate concentrations being higher in the
summer than in the winter (Havard and Reay, 1925).4. Pathogenesis and consequences of hyperphosphatemia in CKD
patients
Hyperphosphatemia is deﬁned as an abnormally high serum
phosphate concentration of >1.46 mmol/L (Wojcicki, 2013).
It is principally observed in patients with reduced kidney func-
tion (Goadby and Stacey, 1934; Hruska et al., 2008). However,
other potential causes exist. These include hypoparathyroidism,
pseudohyperphosphatemia, excessive intake of phosphate,
excessive cellular injury (for example rhabdomyolysis and
tumour lysis syndrome), intracellular shifts (metabolic or respi-
ratory acidosis) and vitamin D toxicity (Mostellar and Tuttle,
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Ron et al., 1984; Albright and Ellsworth, 1929; Bansal et al.,
2014).
Hyperphosphatemia can occur when the kidney function is
impaired to the extent that reduced renal phosphate excretion
and other homoeostatic mechanisms fail to eliminate excess
phosphate (Slatopolsky et al., 1968; Craver et al., 2007;
Slatopolsky et al., 1966).
In CKD, the decline in the glomerular ﬁltration rate (GFR)
is compensated for by an early elevation of the FGF-23
concentration to induce decreased proximal tubule phosphate
re-absorption and attempt to maintain normal phosphate
concentrations (Inoue et al., 2005; Shimada et al., 2004b;
Shimada et al., 2004a; Ix et al., 2010). FGF-23 also reduces
the concentration of 1a, 25(OH)2D3, lowering the effects of
NaPi co-transporters in the intestine and consequently reduc-
ing phosphate absorption (Inoue et al., 2005; Shimada et al.,
2004b; Shimada et al., 2004a).
Phosphate however, can still be absorbed by passive diffu-
sion resulting in an increased inﬂuence on renal mechanisms to
maintain phosphate balance (Danisi et al., 1980). The reduced
concentration of 1a, 25(OH)2D3 leads to a reduction of cal-
cium absorption and stimulates PTH secretion leading to sec-
ondary hyperparathyroidism (SHPT) (Friedlaender et al.,
1983). PTH increases phosphate loss through the kidney by
reducing the number of NaPi co-transporters (Goadby and
Stacey, 1934; O’Donovan et al., 1993).
These compensatory mechanisms attempt to normalise
serum phosphate and calcium concentrations in CKD patients
(Oliveira et al., 2010; Craver et al., 2007). However, as GFR
continues to decline and falls below 25 ml/min, the renal phos-
phate excretion reaches its maximum and excess dietary phos-
phate accumulates leading to persistent hyperphosphatemia
(Slatopolsky et al., 1968). In addition, SHPT and low circulat-
ing 1a, 25(OH)2D3 stimulate bone resorption to a greater
extent than bone formation leading to the loss of bone mineral
density (BMD) and further contributing to hyperphosphate-
mia in CKD patients (Rix et al., 1999; Huffer et al., 1975a;
Huffer et al., 1975b). If the skeletal system does not accommo-
date the increased serum phosphate concentration, serum
phosphate can interact with calcium to precipitate calcium
phosphate salts (hydroxyapatite) in non-skeletal tissues
(McGowan, 1933; Velentzas et al., 1978). Calciﬁcation gener-
ally occurs in the blood vessels, heart valves, myocardium,
and other soft tissues (Bellasi et al., 2012; Ribeiro et al.,
1998; Janigan et al., 2000; Kimura et al., 1999). Cardiovascular
calciﬁcation is probably the main reason for the high preva-
lence of cardiovascular diseases (CVD) in CKD patients as it
cannot be totally explained by the traditional cardiovascular
risks in the general population (Ganesh et al., 2001; Rostand
and Drueke, 1999; Foley et al., 1995; Parfrey and Foley,
1999). CVD accounts for half of all deaths among CKD pop-
ulation (Parfrey and Foley, 1999). Calciﬁcation risk is usually
assessed by the Calcium–Phosphate product (Ca · P)
(Velentzas et al., 1978). A value of 5–6 mmol2/L2 (70 mg2/
dl2) is usually regarded as the ‘threshold’ value above which
calciﬁcation is more likely (Levin and Hoenich, 2001;
Ganesh et al., 2001). Although more likely to occur above this
level, calciﬁcation can occur at (Ca · P) product values of less
than the above threshold (Ribeiro et al., 1998).Observational studies have consistently reported increased
cardiovascular mortality, all-cause mortality, vascular and
valvular calciﬁcations, left ventricular hypertrophy and heart
failure to be associated with increased concentrations of
serum phosphate, PTH, calcium, calcium-phosphate product
(Ca · P) and FGF-23 (Stevens et al., 2004; Tentori et al.,
2008; Slinin et al., 2005; Gutierrez et al., 2008; Hsu and Wu,
2009; Dhingra et al., 2010; McGovern et al., 2013; Block et al.,
2004; Young et al., 2004). A post hoc analysis of the Cholesterol
And Recurrent Events study, found that for 4127 patients with
pervious myocardial infarction, ‘‘a graded independent relation
between phosphate and death’’ existed. The analysis also
reported an association between higher serum phosphate con-
centrations (mostly within the normal range) and increased risk
of cardiovascular diseases and the composite endpoint of death
due to coronary heart diseases (Tonelli et al., 2005).
Persistent hyperphosphatemia and elevated Ca · P product
can also have other negative inﬂuences on haemodynamic vari-
ables such as elevated heart rate, increased diastolic and mean
blood pressures and increased cardiac stroke index (Marchais
et al., 1999).
Giving the signiﬁcant clinical consequences of hyperphos-
phatemia in CKD it is recommended to manage serum
phosphate, serum calcium, Ca · P product and PTH to strict
and speciﬁc targets to reduce the potential impact of such
consequences, improve patients’ quality of life and probably
improve survival (National Kidney Foundation, 2003;
Kidney Disease: Improving Global Outcomes, 2009).
5. Management of hyperphosphatemia in CKD patients
In clinical practice, the management of hyperphosphatemia is
focused on controlling factors that are responsible for the
intake and removal of phosphate from the body. There are
three main strategies for correcting hyperphosphatemia:
I. Diet: restricting dietary phosphate intake.
II. Enhancing elimination: removing phosphate with ade-
quate dialysis.
III. Minimising phosphate absorption: reducing intestinal
absorption using phosphate binders.
5.1. Diet: restricting dietary phosphate intake
Reducing the daily phosphate intake in diet can be challenging
as it is usually incompatible with the recommended daily pro-
tein intake of 1.0–1.2 g/kg/day (National Kidney Foundation,
2000; Kuhlmann, 2007). In addition, the required intensive
patient education, the complexity of dietary tables and book-
lets as well as the substantial variability of phosphate contents
in food from the same category are added challenges for
dietary phosphate control (Kuhlmann, 2007). This makes
diet control alone an insufﬁcient and unreliable technique to
keep phosphate concentrations within the recommended
targets (National Kidney Foundation, 2003; Kidney Disease:
Improving Global Outcomes, 2009). However, when combined
with other strategies, dietary modiﬁcations can assist in
management strategies to help reduce the risk of
hyperphosphatemia (Kuhlmann, 2007).
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Dialysis is the cornerstone of homoeostatic electrolyte man-
agement for end stage renal disease patients. However, the cur-
rently available dialysis techniques are usually ineffective in
removing excess phosphate to the degree of normalising phos-
phate concentration since the rate of transfer of phosphate
from the intracellular pool to the extracellular pool is relatively
slow (DeSoi and Umans, 1993). A rapid reduction in serum
phosphate is seen at the beginning of dialysis (ﬁrst 60–
90 min), but this slows as the concentration gradient between
the plasma and dialysate ﬂuid falls. The rate of phosphate
transfer from the plasma consequently decreases and serum
phosphate levels plateau (DeSoi and Umans, 1993). After dial-
ysis, a signiﬁcant rebound of phosphate can occur (DeSoi and
Umans, 1993) resulting in a potential return to the pre-dialysis
serum phosphate concentrations (DeSoi and Umans, 1993).
Removal of phosphate will also depend on the type and
extent of dialysis performed.
For example the elimination of phosphate ranges between
300 and 1200 mg per day depending of the type of dialysis
used: A standard 4 h haemodialysis treatment removes
between 600 and 1200 mg/day (1800–3600 mg/week) compared
to continuous ambulatory peritoneal dialysis which removes
between 300 and 360 mg/day (2100–2520 mg/week) (Bellasi
et al., 2006).
Modifying the dialysis frequency and length of treatment
may improve efﬁciency. Two studies have shown a signiﬁcant
lowering of phosphate levels using innovative dialysis tech-
niques (Ayus et al., 2005; Mucsi et al., 1998). One study trialled
the short daily haemodialysis (six 3-h sessions per week) (Ayus
et al., 2005) while the other trialled nocturnal haemodialysis
(six night-sessions per week for 8–10 h each while the patient
is sleeping) (Mucsi et al., 1998). Both of these dialysis tech-
niques are still investigational and their applicability and effec-
tiveness as alternatives to the conventional dialysis techniques
in the management of hyperphosphatemia yet to be
determined.
In summary, dialysis treatments even when combined with
dietary phosphate restriction are usually ineffective in manag-
ing hyperphosphatemia. Most dialysis patients require phos-
phate binders to control their hyperphosphatemia.
5.3. Minimising phosphate absorption: reducing intestinal
absorption (phosphate binders)
Using phosphate binders to assist in the management of hyper-
phosphatemia in patients undergoing dialysis is common with
more than 95% of patients being prescribed phosphate binders
(Elseviers and De Vos, 2009). Phosphate binders work by
binding dietary phosphate and forming insoluble complexes
that are excreted by the gut (Tonelli et al., 2010; Hutchison
et al., 2011).
The most commonly utilised phosphate binders are:
(Tonelli et al., 2010; Elseviers and De Vos, 2009).
a. Calcium-based phosphate binders (calcium carbonate
and calcium acetate).
b. Non-absorbable polymers (sevelamer).c. Heavy metal salts (lanthanum carbonate and aluminium
hydroxide).
5.3.1. Calcium-based phosphate binders
Calcium-based phosphate binders are the most widely pre-
scribed phosphate binders (Elseviers and De Vos, 2009). They
are more effective than placebo in reducing serum phosphate
concentrations and PTH (Rudnicki et al., 1993). However, large
doses of calcium-based binders (up to 17 g per day) are usually
required to achieve adequate phosphate management (Chiu
et al., 2009; Slatopolsky et al., 1986). This translates to high pill
burden (for example a dose of 17 g of calcium carbonate would
require approximately 13 tablets) to deliver the required doses
(Chiu et al., 2009; Slatopolsky et al., 1986). In addition, their
use is potentially associated with hypercalcaemia and calciﬁca-
tion of vascular tissues (Delmez et al., 1992). This is of particu-
lar concern when these calcium-based phosphate binders are
prescribed with vitamin D (Delmez et al., 1992).
Several studies have investigated the relationship between
increased calcium load serum calcium concentration and over-
all mortality. A large study of 40,538 haemodialysis patients
reported a direct relationship with each 0.25 mmol/l increase
in serum calcium associated with a 20% increase in relative
risk of death (Block et al., 2004). Other studies have also found
a relationship between an increase in the calcium load and the
progression of vascular calciﬁcation especially in patients with
low-turnover bone diseases (Chertow et al., 2002; Chertow
et al., 2004; London et al., 2008).
5.3.2. Non-absorbable polymers (sevelamer)
Sevelamer hydrochloride was the ﬁrst member of its class to be
marketed. It is a non-absorbable, synthetic ion-exchange poly-
mer that binds phosphate and inhibits its absorption by the
body (Hutchison et al., 2011). Polymers are considered to be
as effective as the calcium-based phosphate binders (Chertow
et al., 2002) but are much more expensive and have signiﬁcant
gastrointestinal side effects (Madan et al., 2008).
The possibility of hypercalcaemia and lowered concentra-
tions of PTH are less likely to occur with sevelamer
(Chertow et al., 2002). In addition, the ‘Treat to Goal Study’
(200 haemodialysis patients) found a signiﬁcant reduction in
the progression of vascular calciﬁcation in the sevelamer-trea-
ted group compared with the calcium-containing binders trea-
ted group over the 52-week study period (Chertow et al., 2002).
Proposed other beneﬁts with sevelamer are an anti-inﬂam-
matory effect, a favourable effect on the blood lipid proﬁle
(due to an ability to bind with cholesterol in the GIT), and a
reduction in uric acid (Chertow et al., 1999; Ferramosca
et al., 2005; Garg et al., 2005).
Despite these advantages, the relatively high price and high
tablet burden as well as the gastrointestinal side effects are the
main drawbacks for the use of sevelamer in the management of
hyperphosphatemia in CKD patients (Chiu et al., 2009;
Madan et al., 2008).
5.3.3. Heavy metal salts (lanthanum carbonate and aluminium
hydroxide)
5.3.3.1. Lanthanum carbonate (LC). Lanthanum carbonate
(LC) is a relatively new agent that has been approved as a
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earth element’’ that has been shown to be effective in binding
phosphate and consequently managing hyperphosphatemia
(Albaaj and Hutchison, 2005). The risk of accumulation in
the body was shown to be minimal as only 0.00005% of lan-
thanum was found to be absorbed by canine intestine
(Albaaj and Hutchison, 2005). In a one-year randomised
study, lanthanum improved bone diseases (conﬁrmed by bone
biopsies) as compared with calcium carbonate (D’Haese et al.,
2003). However, the risk of accumulation has not been ade-
quately studied in CKD patients and there is limited data on
the effect of LC on bone histology over a longer treatment per-
iod (Bellasi et al., 2006). The risk of neurological damage
should be low with LC since it does not cross the blood brain
barrier (Albaaj and Hutchison, 2005).
Clinical studies have found LC to be a well-tolerated phos-
phate binder with minimal gastrointestinal side effects (Joy
et al., 2003; Hutchison et al., 2004). Doses of 375–3000 mg/
day have been able to reduce phosphate, Ca · P product and
PTH concentrations in a dose-dependent fashion as compared
with placebo (Joy et al., 2003).
In a head to head comparison with calcium carbonate, LC
(750–3000 mg/day) has been shown to be equally effective as
calcium carbonate (1500–3000 mg/day), achieving optimal
phosphate control in approximately 65% of participants
(n = 800) (Hutchison et al., 2005). However as would
expected, LC was shown to be superior in reducing the inci-
dence of hypercalcaemia (0.4% vs. 20.2%; p< 0.001) and cal-
cium · phosphate product (Hutchison et al., 2005). Finn et al.,
have reported a LC to be safe, effective and tolerable in a study
conducted over a three-year period (Finn et al., 2005).
In summary LC is a promising phosphate binder. Addi-
tional studies are needed to conﬁrm its long-term safety proﬁle
and role in preventing vascular calciﬁcation (Bellasi et al.,
2006).
5.3.3.2. Aluminium salts. Aluminium containing phosphate
binders are highly effective. However, they have considerable
side effects that have signiﬁcantly limited their use. They have
been associated with anaemia, dementia, encephalopathy and
bone disease (Monier-Faugere and Malluche, 1996; Alfrey
et al., 1976; von Bonsdorff et al., 1990). Currently, their use
is conﬁned to short-term management of hyperphosphatemia
in cases resistant to other approaches (National Kidney
Foundation, 2003).
In summary, Phosphate binders are the corner stone for the
management of hyperphosphatemia in patients with CKD. All
phosphate binders have been found to be equally effective in
terms of phosphate control if given in equivalent doses
(Navaneethan et al., 2011). Calcium based binders are most
widely used because of their availability and affordability.
However, they increase the risk of hypercalcaemia and the pro-
gression of vascular calciﬁcation and hence, may not be suit-
able binders in patients with hypercalcaemia or dialysis
patients with advanced calciﬁcations. Sevelamer and lantha-
num do not appear to increase the risk of hypercalcaemia
but they are relatively more expensive than calcium based
binders. Both are felt to improve bone diseases in CKD
patients, but long term studies are lacking. Sevelamer reduces
the progression of calciﬁcation but lanthanum, however, is not
yet studied in this regard. Aluminium is only used for short-
term hyperphosphatemia management (National KidneyFoundation, 2003; Kidney Disease: Improving Global
Outcomes, 2009).
5.4. Other signiﬁcant medications affecting phosphate
Active vitamin D sterols such as calcitriol and alfacalcidol and
their analogues (paricalcitol, doxercalciferol, 22-oxacalcitriol
and maxacalcitol) are used to treat SHPT in CKD patients
(Brickman et al., 1972; Chalmers et al., 1973; Tamura et al.,
2005). They directly inhibit the secretion of PTH through the
activation of vitamin D receptors in parathyroid glands
(Martin et al., 1998). However, they increase the absorption
of both calcium and phosphate (vitamin D analogues to a
lesser extent) and thus may complicate hyperphosphatemia
management and promote calciﬁcations in CKD patients
(Brickman et al., 1972; Chalmers et al., 1973; Sprague et al.,
2003; Tamura et al., 2005; Martin et al., 1998).
Cinacalcet is a calcimimetic agent that binds and modulates
calcium-sensing receptors in parathyroid glands resulting in
reduction of PTH secretion and regression of parathyroid
glands proliferation (Moe et al., 2005b). It is used to treat sec-
ondary hyperparathyroidism (SHPT) in patients with CKD
(Moe et al., 2005b). Unlike vitamin D sterols, its use is associ-
ated with reduced phosphate concentrations, Ca · P product
and calcium concentrations in haemodialysis patients (Moe
et al., 2005a; Moe et al., 2005b; Lindberg et al., 2003).6. Reasons for failure of phosphate control
Despite an increased understanding of the physiological pro-
cesses involved in phosphate homoeostasis and improved ther-
apy for the prevention and treatment of hyperphosphotaemia
in CKD patients more than 50% of dialysis patients have their
serum phosphate concentrations above the recommended tar-
get range of 1.13–1.78 mmol/L (Young et al., 2004; National
Kidney Foundation, 2003). Schaefer has provided ten possible
reasons for this failure: (Schaefer, 1994).
1. Pseudohyperphosphataemia (incorrect sample handling;
analytical error).
2. High dietary phosphate intake.
3. High doses of active vitamin D metabolites.
4. Phosphate-containing drugs (enema, infusion).
5. Inadequacy of haemodialysis.
6. Advanced osteitis ﬁbrosa (efﬂux of P from bone inde-
pendent of intestinal P uptake).
7. Metabolic acidosis (phosphate shift from intracellular
into extracellular space).
8. Patient non-compliance with phosphate binders.
9. Incorrect intake of phosphate binders (timing and
dosing).
10. Inefﬁciency of calcium carbonate because of achlorhyd-
ria (spontaneous or after medication).
Although as listed above there are many interacting and
overlapping reasons for hyperphosphotaemia in CKD
patients, the inﬂuence of intestinal pH on calcium and phos-
phate absorption as well as on the potential efﬁciency of phos-
phate binders is of special interest.
Potential inﬂuences on binding efﬁciency are based on the
following observations:
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calcium and phosphate.
(2) All phosphate binding agents, with the exception of
sevelamer, act as antacids and can affect the pH.
(3) CKD patients are frequent users of acid suppressing
drugs such as antacids, PPIs and H2-blockers.
The theory of an inﬂuence of pH on the absorption of cal-
cium and phosphorous from dietary sources was reported in
the 1930’s (McGowan, 1933; Patwardhan and Nhavi, 1939).
The rate (but not the extent) of phosphate absorption was
reported to be inﬂuenced by the pH of the canine stomach con-
tents since different phosphate species exist in the intestinal
tracts that have different absorption proﬁles at different pH
ranges (Patwardhan and Nhavi, 1939). In the presence of excess
calcium, pH can be neutralised with the production of a non-
absorbable insoluble calcium phosphate salt (McGowan,
1933). If the pH is acidic, and calcium and phosphate are pres-
ent in moderate and equal quantities then both will be soluble
and able to be absorbed together (McGowan, 1933).
Calcium carbonate, aluminium and magnesium salts have
been used for many years as over-the-counter antacid prepara-
tions (Rey et al., 2004) and lanthanum carbonate was also
found to have an antacid action (Damment, 2011). Calcium
carbonate, based on its acid neutralising capacity, is consid-
ered to be the most potent single antacid available (Maton
and Burton, 1999) and reacts with gastric acid to form calcium
chloride (CaCl2) according to the following equation
(Fordtran and Locklear, 1966; Sheikh et al., 1989):
CaCO3 þ 2HCl! CaCl2 þ CO2 þH2O
This more water-soluble calcium salt form is able to bind
phosphate in the gut and provide calcium for absorption
(Sheikh et al., 1989). This suggests that in a non-acidic envi-
ronment the insoluble calcium carbonate will not be able to
dissociate into free calcium ions that will bind phosphate to
form an insoluble and hence non-absorbable salt in the
absence of HCl (Sheikh et al., 1989).
This issue is of particular concern in dialysis patients as
they are commonly prescribed gastric acid suppressive medica-
tions to control gastrointestinal symptoms which are common
in these patients (Strid et al., 2002; Strid et al., 2003; Hammer
et al., 1998). Medications such as H2-blockers (e.g. cimetidine,
famotidine, ranitidine and nizatidine) and proton pump inhib-
itors (PPIs) (e.g. esomeprazole, lansoprazole, omeprazole and
pantoprazole) are widely prescribed to dialysis patients.
A study by Strid et al. reported a higher and inappropriate
use of acid suppressive medications in dialysis patients as
compared with other hospitalised patients (41% vs 13%;
p< 0.001) (Strid et al., 2003).
In conclusion, there is a high risk for a potentially signiﬁ-
cant interaction between acid suppressant and phosphate-
binding drugs given the high rates of co-administration in
CKD and dialysis patients.
7. Conclusion
Hyperphosphatemia in CKD patients is an important compli-
cation of reduced kidney function. It is associated with severe
clinical consequences including cardiovascular tissues calciﬁ-
cation, bone diseases, and secondary hyperparathyroidismleading to increased cardiovascular diseases and mortality
rates. Therefore, dietary phosphate restrictions, adequate dial-
ysis and phosphate binders are usually combined for effective
management of hyperphosphatemia. However, attainment of
phosphate control targets is difﬁcult and may not be achieved
in many patients. The efﬁcacy of phosphate binders, especially
calcium carbonate, may be inﬂuenced by the co-administration
of acid suppressant drugs and thus, clinicians should be aware
of the potential of such interaction and review all CKD
patients for inappropriate use of acid suppressive medications.
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